NCT02989064View on ClinicalTrials.gov

MAGE-A10ᶜ⁷⁹⁶T for Urothelial Cancer, Melanoma or Head and Neck Cancers

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

October 31, 2016

Primary Completion Date

December 18, 2019

Study Completion Date

June 4, 2020

Conditions
Urothelial CarcinomaHead and Neck CancerMelanomaBladder Urothelial Carcinoma
Interventions
GENETIC

Autologous genetically modified MAGE A10ᶜ⁷⁹⁶T cells

Infusion of autologous genetically modified MAGE A10ᶜ⁷⁹⁶T on Day 1

Trial Locations (11)

14263

Roswell Park Cancer Institute, Buffalo

19111

Fox Chase Cancer Center, Philadelphia

28040

Start Madrid-FJD, Fundación Jimѐnez Díaz, Madrid

28041

Hospital Universitario 12 Octubre Avda. de Córdoba, Madrid

37203

Tennessee Oncology - Sarah Cannon Research Institute, Nashville

Vanderbilt - Ingram Cancer Center, Nashville

43210

Ohio State University Wexner Medical Center, Columbus

63110

Washington University - School of Medicine, St Louis

77030

MD Anderson Cancer Center, Houston

02114

Massachusetts General Hospital, Boston

M5G1X6

Princess Margaret Cancer Centre, Toronto

Sponsors

Lead Sponsor

Adaptimmune
All Listed Sponsors
lead

Adaptimmune

INDUSTRY

NCT02989064 - MAGE-A10ᶜ⁷⁹⁶T for Urothelial Cancer, Melanoma or Head and Neck Cancers | Biotech Hunter | Biotech Hunter